Member Info for DeBull

04.56 talks of "on the cusp" of setting up a new trial to test a new case for the tool.

A lot more than 5 from the UK Laura.... https://informaconnect.com/uploads/BIO-Europe-2024-Attendee-List-1102-7dc6fa3c5a6d38aea9e8d3095a721b38.pdf

Same amount, same price, same time stamp.

Thanks. Thought you were referring to the last RNS re CRUK, but you meant the last Bicycle RNS back in March?

March = contract with Bicycle (CRUK also named in it)

Oct = contract with CRUK

Are the 2 interlinked or standalone targets?

King, can you elaborate on this comment please?

I know PYC worked on BT1718.

MT1-MMP as mentioned in the Bicycle link goes to this https://www.bicycletherapeutics.com/wp-content/uploads/2022/07/Oct232019_MT1MMP_TRIPLEposter_FINAL.pdf

Where does the CRUK RNS fir with the Bicycle link please?

What is a concern is that my post got 1 like, and 888's post of posters having brain trauma gets 4 likes.

888. You may think that your comment is in "jest" however, the notion that having any brain tumour, terminal or not is nothing to "jest" about. Just because someone says something which you may not agree with, should not imply of a terminal disease.

Https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-strategy-and-portfolio

Pipeline for CRUK. any of those listed or those not shown could be a candidate from the RNS earlier in the month?

I know Laura about the omission of a name. I get it, but you said some of the last contracts had the "trinity" but due to NDA's, client confidentiality etc the "trinity" is rarely seen in the RNS. My post to GB was not a "dig" it was a observation and answer to one of their Q's

Thank you King, the quickest solution to part of the problem is for the BOD to buy some shares? That should inject some much needed confidence within the existing and wider shareholder base??

I know Laura has pointed out that they have one of the lowest pay structures within AIM.

Laura, either "existing client" or "new UK based biotech" so the exact name of the company associated with these contracts is missing. We can only make assumptions of who they could be.

Gordon, some do, most do not.

As i said a few days ago, we all want the holy trinity of RNS details here, ie price, length and name associated with contract. PYC rarely get all 3, normally we get 1-2. The CRUK last week, just mentioned CRUK and the rest is guess work

ATT001 is from Ariceum Therapeutics.

The trial is from UCLH

We have a working relationship with Merck with their DNA damage drug.

Conclusion: The extended model captured shortening of neutropenia due to GCSF co-medication. It also captured a general trend in lesser severity and earlier occurrence of nadir compared to docetaxel treatment alone. Prediction of precise ANC levels and timing of GCSF administration require model refinement, warranting further study and additional clinical data.

I believe this is the poster they are presenting?

https://cm.eortc.org/cmEpostersV2/ENA2024.html#/PosterDetail/392

Ralph / King so the RNS was from last year early 2023? The webpage found by King is similar, but with no date associated with it?

King seems to think the information on the webpage is not great, as no more updates etc? Can this be clarified?

As Laura says, they a presenting this, or something similar at the conference today / tomorrow. Until we see the poster or its contents we will not know what it says.

KingH, when was this publsihed? I cant find a date anywhere in the article or source code?

The 2 x 1m+ trades have to be B&I they so very close together and there is only 32 seconds between the trades. BWTHDIK

Toffee123, thank you for the explanation. Have wondered why with all this .65 trades, the SP has not budged. Yet we have another poster who states they have bought at .65. The analogy of a "iceberg" sell is intriguing. However with 203m shares in issue, it would only take someone to buy near 7m to go over 3% so triggering TR1? When you say a possibility of someone looking to get 10's of millions, that would mean them getting say a minimum of 30m shares , they would have over 12% of the company?? Is that right?

Just shows how much investors thinks about PYC? As stated, VAL up 75%, and nearly 3M sells here? A lot of sells after the presentation , and after VAL moved. Maybe some here bailed and went to VAL??

Orphan status for Cellcentrics Inobrodib which PYC worked on

Notice that on the Linkedin post about the Barcelona conference, Tim Corn who is a NED here wrote " Great opportunity"